AstraZeneca drops lead project but not interest in Palatin obesity alliance
This article was originally published in Scrip
Executive Summary
AstraZeneca has ended development of the obesity drug AZD2820 from its collaboration with Palatin Technologies following an earlier reported serious adverse event (SAE) during Phase I testing, but the partners will continue to advance other melanocortin agonists for the treatment of obesity.